Holen Sie sich die Stockscreener-App
71.23
1.06%
-0.76
Handel nachbörslich:
71.23
Schlusskurs vom Vortag:
$71.99
Offen:
$71.35
24-Stunden-Volumen:
219.22K
Relative Volume:
0.65
Marktkapitalisierung:
$1.64B
Einnahmen:
$923.71M
Nettoeinkommen (Verlust:
$84.68M
KGV:
18.07
EPS:
3.9419
Netto-Cashflow:
$182.81M
1W Leistung:
-2.20%
1M Leistung:
-10.06%
6M Leistung:
-6.93%
1J Leistung:
-25.80%
1-Tages-Spanne:
$71.11
$72.06
1-Wochen-Bereich:
$71.11
$74.99
52-Wochen-Spanne:
$70.15
$99.50
Ani Pharmaceuticals Inc Stock (ANIP) Company Profile
Firmenname
Ani Pharmaceuticals Inc
Sektor
Telefon
(609) 759-1810
Adresse
104 CARNEGIE CENTER DRIVE SUITE 300, PRINCETON, MN
Compare ANIP vs TAK, TEVA, HLN, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ANIP
Ani Pharmaceuticals Inc
|
71.23 | 1.78B | 923.71M | 84.68M | 182.81M | 3.9419 |
TAK
Takeda Pharmaceutical Co Adr
|
18.45 | 57.90B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
36.36 | 42.89B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.60 | 43.41B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
75.81 | 31.00B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
487.61 | 22.35B | 3.17B | 1.29B | 1.01B | 27.09 |
Ani Pharmaceuticals Inc Stock (ANIP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-10 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-03-14 | Eingeleitet | Jefferies | Buy |
| 2025-03-12 | Eingeleitet | JP Morgan | Overweight |
| 2024-12-11 | Eingeleitet | Leerink Partners | Outperform |
| 2024-10-11 | Eingeleitet | Piper Sandler | Overweight |
| 2024-03-15 | Eingeleitet | CapitalOne | Overweight |
| 2023-08-22 | Bestätigt | H.C. Wainwright | Buy |
| 2023-03-01 | Eingeleitet | Guggenheim | Buy |
| 2022-09-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-11-02 | Eingeleitet | Truist | Buy |
| 2020-05-07 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2019-09-12 | Eingeleitet | Guggenheim | Buy |
| 2019-05-10 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2017-10-16 | Bestätigt | Canaccord Genuity | Buy |
| 2017-07-31 | Eingeleitet | Canaccord Genuity | Buy |
| 2017-02-22 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2016-06-23 | Eingeleitet | Raymond James | Strong Buy |
| 2016-05-24 | Herabstufung | Standpoint Research | Buy → Hold |
| 2015-11-13 | Eingeleitet | Standpoint Research | Buy |
| 2015-09-28 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2015-08-05 | Bestätigt | Oppenheimer | Outperform |
| 2015-08-04 | Bestätigt | ROTH Capital | Neutral |
| 2015-07-31 | Bestätigt | Oppenheimer | Outperform |
| 2015-07-15 | Bestätigt | ROTH Capital | Neutral |
| 2015-06-23 | Bestätigt | Oppenheimer | Outperform |
| 2015-05-18 | Bestätigt | ROTH Capital | Neutral |
| 2015-05-06 | Bestätigt | Oppenheimer | Outperform |
| 2015-04-10 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2015-02-26 | Bestätigt | ROTH Capital | Buy |
| 2015-02-18 | Bestätigt | Oppenheimer | Outperform |
Alle ansehen
Ani Pharmaceuticals Inc Aktie (ANIP) Neueste Nachrichten
NFJ Investment Group LLC Takes $2.77 Million Position in ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
Virtus Advisers LLC Makes New Investment in ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
Quartz Partners LLC Makes New $1.61 Million Investment in ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
Great Lakes Advisors LLC Buys Shares of 61,481 ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
Aurora Investment Counsel Takes Position in ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
ANI (ANIP): Rises 1.37% to $77.92 for the Current Session; Boundary Watch: $74.02 and $81.82 Define the Nearby Reference Levels for the Current SessionHigh Dividend Factor - Vinanet
ANI Pharmaceuticals (NASDAQ:ANIP): What Could Shift Sentiment? - Kalkine Media
Rice Hall James & Associates LLC Takes Position in ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
ANI Pharmaceuticals (ANIP) Q2 2026 Earnings Call Transcript - AOL.com
The Top 5 Analyst Questions From ANI Pharmaceuticals’s Q2 Earnings Call - Yahoo Finance
ANI Pharmaceuticals (ANIP) Could Be 34% Undervalued As Earnings And Guidance Hold - Sahm
Winners And Losers Of Q2: ANI Pharmaceuticals (NASDAQ:ANIP) Vs The Rest Of The Generic Pharmaceuticals Stocks - Yahoo Finance
Walleye Capital LLC Buys Shares of 106,112 ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
Should You Buy ANIP as Low Valuation Meets Cortrophin Execution Risk? - TradingView
ANIP's Cortrophin Guidance Cut Raises the Bar for Second-Half Growth - Yahoo Finance
ANI Pharmaceuticals (ANIP) Insider Sell: SR. VP, GENERAL COUNSEL & SEC. Meredith Cook Sells 500 Shares - GuruFocus
ANI Pharmaceuticals Senior VP Meredith Cook Sells 500 Shares via 10b5-1 Trading Plan - Kalkine Media
Meredith Cook Sells 500 Shares of ANI Pharmaceuticals (NASDAQ:ANIP) Stock - MarketBeat
ANI Pharmaceuticals (ANIP) counsel Meredith Cook sells 500 shares under 10b5-1 plan - Stock Titan
Amundi Has $352,000 Holdings in ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
Ani Pharmaceuticals SVP Ori Gutwerg sells $243,474 in common stock. By Investing.com - Investing.com Australia
Ori Gutwerg Sells 3,162 Shares of ANI Pharmaceuticals (NASDAQ:ANIP) Stock - MarketBeat
Ani Pharmaceuticals SVP Ori Gutwerg sells $243,474 in common stock. - Investing.com
ANI Pharmaceuticals (ANIP) SVP, Generics Ori Gutwerg Sells 3,162 Shares - GuruFocus
ANI Pharma SVP, Generics Ori Gutwerg reports sale of 3,162 common shares worth $243,474 - Bitget
ANI Pharmaceuticals (ANIP) SVP Ori Gutwerg sells 3,162 shares at $77 - Stock Titan
ANIP Q2 Deep Dive: Rare Disease Expansion Drives Growth Amid Guidance Recalibration - Yahoo Finance
Analysts cut ANI Pharmaceuticals targets despite Q2 earnings beat - scanx.trade
Guggenheim cuts ANI Pharmaceuticals stock price target on Cortrophin guidance - Investing.com
Canaccord Genuity Group Cuts ANI Pharmaceuticals (NASDAQ:ANIP) Price Target to $90.00 - MarketBeat
Canaccord cuts ANI Pharmaceuticals stock price target on Cortrophin miss By Investing.com - Investing.com Canada
ANI Pharmaceuticals (NASDAQ:ANIP): What Could Today Reveal? - Kalkine Media
ANI Pharmaceuticals Inc (ANIP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
ANI Pharmaceuticals (ANIP) Could Be 31% Undervalued On Strong Q2 Results And Guidance Reset - finance.yahoo.com
ANI Pharmaceuticals, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:ANIP) 2026-08-08 - Seeking Alpha
ANI Pharmaceuticals (NASDAQ:ANIP) Stock Rating Lowered by Wall Street Zen - MarketBeat
ANI Pharmaceuticals (NASDAQ:ANIP) Announces Earnings Results - MarketBeat
ANI Pharmaceuticals’s (NASDAQ:ANIP) Q2 CY2026 Sales Beat Estimates But Stock Drops On Weak Guidance - webull.com
ANI Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
ANI Pharmaceuticals, Inc. Stock 12‑Month Price Target Cut to $109.12, Implies 32% Upside - TradingView
Earnings call transcript: ANI Pharmaceuticals beats Q2 2026 estimates, shares fall premarket - Investing.com
ANI Pharmaceuticals Q2 2026 slides: record results, gout expansion underway - Investing.com Nigeria
ANI Pharmaceuticals Inc (ANIP) (Q2 2026) Earnings Call Highlights: Record Revenue and Strategic ... - Yahoo Finance
ANI Pharmaceuticals Announces Q2 2026 Earnings and Releases Updated Investor Presentation - Kalkine Media
ANI Pharmaceuticals, Inc (ANIP) Q2 2026 Earnings Call Transcript - AlphaStreet
ANI Pharmaceuticals Q2 2026 Earnings Call Transcript - MarketBeat
ANI Pharmaceuticals (NASDAQ:ANIP) Guidance Signals Fresh Momentum - Kalkine Media
ANI Pharmaceuticals (NASDAQ:ANIP) Shares Gap DownHere's Why - marketbeat.com
ANI Pharmaceuticals Q2 Earnings Call Highlights - marketbeat.com
ANI Pharmaceuticals Shares Slide Despite Earnings Beat After Cortrophin Outlook Cut - Yahoo Finance
Finanzdaten der Ani Pharmaceuticals Inc-Aktie (ANIP)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.66%
0.33%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):